샘플 요청 목록

 카트 문의
시장보고서
상품코드
1798843

세계의 치매 치료제 시장

Dementia Drugs
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 286 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

치매 치료제 세계 시장은 2030년까지 212억 달러에 달할 전망

2024년에 160억 달러로 추정되는 치매 치료제 세계 시장은 2024년부터 2030년까지 CAGR 4.9%로 성장하여 2030년에는 212억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 루이소체 치매는 CAGR 3.8%를 기록하며 분석 기간 종료시에는 77억 달러에 달할 것으로 예측됩니다. 파킨슨병 치매 부문의 성장률은 분석 기간 동안 CAGR 6.1%로 추정됩니다.

미국 시장은 43억 달러로 추정, 중국은 CAGR 7.6%로 성장 예측

미국의 치매 치료제 시장은 2024년에 43억 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 41억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 7.6%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 2.4%와 4.8%로 예측됩니다. 유럽에서는 독일이 CAGR 3.1%로 성장할 것으로 예측됩니다.

세계의 치매 치료제 시장 - 주요 동향과 촉진요인 정리

치매 치료제에 대한 수요가 전 세계 보건의 중요한 이슈가 되고 있는 이유는 무엇일까?

주로 기억, 인지, 행동에 영향을 미치는 진행성 신경 퇴행성 질환인 치매는 가장 시급한 세계 공중보건 문제로 인식되고 있습니다. 특히 선진국과 신흥경제국에서는 인구의 고령화에 따라 치매 유병률이 빠르게 증가하고 있으며, 그 중 알츠하이머병이 그 대부분을 차지하고 있습니다. 치매의 사회적, 경제적 부담은 헤아릴 수 없을 정도로 환자뿐만 아니라 가족, 간병인, 의료 시스템에도 영향을 미치고 있습니다. 이러한 유병률 증가로 인해 질병의 진행을 늦추고 증상을 관리하며 삶의 질을 개선할 수 있는 효과적인 약리학적 치료법에 대한 수요가 급증하고 있습니다. 현재 사용 가능한 치매 치료제는 근본적인 병인보다는 신경전달물질의 불균형이나 행동의 합병증에 대처하는 대증요법이 주를 이룹니다. 그러나 아밀로이드 플라크, 타우 엉킴, 신경염증 경로를 표적으로 하는 질병 변형 치료제의 연구개발은 그 시급성이 높아져 집중적으로 이루어지고 있습니다. 근본적인 치료법이 없고, 다른 노화 관련 질환과 동반되는 경우가 많은 이 질환의 복잡한 특성으로 인해 더 나은 관리 방법의 필요성이 대두되고 있습니다. 조기 진단 노력과 인식 개선 캠페인으로 더 많은 사람들이 조기에 치료를 받을 수 있게 되었고, 약물 치료 대상 환자층이 확대되고 있습니다. 의료 서비스 제공자와 정책 입안자들은 치매 관리를 점점 더 우선순위에 두고 있으며, 그 결과 임상시험에 대한 자금 지원과 종합적인 건강 관리 계획이 증가하고 있습니다. 이러한 인구통계학적, 사회적, 의학적 요인의 수렴으로 치매 치료제 시장은 광범위한 신경치료제 분야에서 장기적인 전략적 중요성을 갖는 초점이 되고 있습니다.

과학기술의 발전은 치매 치료제 개발의 미래를 어떻게 형성하고 있는가?

신경과학, 분자생물학, 생명공학의 발전은 치매 치료제 개발의 궤도를 바꾸고 있으며, 인지기능 저하의 근본 원인을 해결할 수 있는 새로운 희망을 가져다주고 있습니다. 최근에는 기존의 콜린에스테라아제 억제제나 NMDA 수용체 길항제뿐만 아니라 아밀로이드 베타 응집, 타우 단백질 인산화, 시냅스 가소성, 신경염증 등 새로운 타겟의 탐색으로 연구가 확대되고 있습니다. 유전체학과 단백질체학의 비약적인 발전으로 다양한 치매 관련 바이오마커와 유전적 위험인자가 규명되어 보다 개인화된 맞춤형 치료제 개발이 가능해졌습니다. PET 스캔이나 MRI를 이용한 체적 분석과 같은 첨단 영상 진단 기술의 도입으로 보다 빠른 진단과 보다 정확한 질병 진행 추적이 가능해졌으며, 이는 새로운 치료법의 효과를 평가하는 데 매우 중요한 역할을 합니다. 임상시험 설계도 진화하고 있으며, 적응증 시험 모델, 실제 데이터 통합, 디지털 인지 평가 도구 등은 연구자들이 보다 의미 있고 시의적절한 결과를 수집할 수 있도록 돕고 있습니다. 이와 함께 제약사들은 인공지능과 머신러닝을 활용하여 화합물 탐색 가속화, 치료 결과 예측, 임상시험 모집 최적화를 위해 노력하고 있습니다. 아밀로이드 단백질과 타우 단백질을 표적으로 하는 생물학적 제제와 단클론항체가 규제 당국의 파이프라인을 통과하고 있으며, 이는 질병 변형 전략으로의 전환을 시사하고 있습니다. 찬반양론에도 불구하고 일부 시장에서는 아밀로이드를 표적으로 하는 약물이 빠르게 승인되면서 이 분야에 대한 관심과 투자가 새롭게 증가하고 있습니다. 또한, 여러 병태생리 과정을 동시에 다루는 병용요법은 치매 치료의 보다 종합적인 접근법으로 각광받고 있습니다. 이러한 과학기술의 혁신은 치료의 가능성을 넓힐 뿐만 아니라 치매 치료제 시장의 유효성과 안전성의 기준을 재정의하고 있습니다.

치매 치료제 시장 확대와 투자를 촉진하는 트렌드는 무엇일까?

세계 치매 치료제 시장의 확대는 인구통계, 헬스케어 우선순위, 투자 전략의 변화를 반영하는 여러 트렌드가 복합적으로 작용하고 있습니다. 가장 영향력 있는 트렌드 중 하나는 고령화이며, 특히 북미, 유럽, 일본, 그리고 평균 수명이 길어지고 있는 아시아 및 라틴아메리카 일부 지역에서 두드러지게 나타나고 있습니다. 치매의 가장 큰 위험요인은 노화이기 때문에 이러한 인구통계학적 변화는 환자 수 증가와 치료 솔루션의 지속적인 시장 확대로 이어지고 있습니다. 동시에 알츠하이머병 협회, 세계보건기구(WHO) 등의 단체가 주도하는 인식 개선 캠페인과 교육 활동은 편견을 없애고 조기 검진을 장려하며 진단율을 높이고 있습니다. 의료 시스템은 노인 정기검진에 인지기능 검진을 포함시키고, 치매 관련 치료에 대한 보험 적용을 확대하는 등 적응하고 있습니다. 또한, 벤처 캐피털과 대형 제약사들이 신경학 및 신경퇴행성 질환 연구에 다시 관심을 보이는 등 투자자 심리의 변화도 눈에 띕니다. 생명공학 스타트업과 기존 제약사와의 전략적 파트너십이 보편화되고 있으며, 이를 통해 보다 빠른 기술 혁신과 광범위한 임상 개발이 가능해졌습니다. 또한, 여러 국가의 규제 당국이 치매 치료, 특히 미충족 의료 수요에 대응하는 치료제의 승인에 유연성을 보이고 있어 유망한 후보 약물의 시장 진입이 가속화되고 있습니다. 시장의 다변화도 트렌드 중 하나이며, 알츠하이머병 외에도 혈관성 치매, 전두측두엽형 치매, 레비소체형 치매 등 다양한 유형의 치매에 대한 개발사들의 움직임이 활발히 진행되고 있습니다. 이러한 치료 영역의 확장으로 시장은 보다 광범위한 임상 증상과 환자들의 요구에 부응하며 역동적으로 변화하고 있습니다.

세계 치매 치료제 시장의 성장을 촉진하는 주요 요인은 무엇인가?

치매 치료제 시장의 성장은 의료, 인구통계, 기술, 경제 등 다양한 요인이 복합적으로 작용하고 있습니다. 특히 신흥 경제국에서는 고령화와 장수화로 인해 치매 환자가 전 세계적으로 급증하고 있습니다. 이러한 인구통계학적 변화로 인해 장기적인 치료가 필요한 환자층이 지속적으로 확대되고 있으며, 효과적인 약리학적 치료에 대한 수요가 증가하고 있습니다. 또 다른 중요한 원동력은 조기 진단에 대한 관심이 높아지고 있으며, 이는 영상 진단, 바이오마커 식별, 인지 평가 도구의 개선으로 촉진되고 있습니다. 조기 개입은 치료 효과의 가능성을 높이고, 예방 및 질병 변형 전략의 문을 열어줍니다. 제약회사와 생명공학 기업들은 정부 보조금과 자선단체의 자금 지원을 받아 연구개발에 적극적으로 투자하며 이 기회에 부응하고 있습니다. 미충족 수요가 큰 의약품에 대한 신속한 승인 경로를 지원하는 진화하는 규제 프레임워크도 혁신을 더욱 촉진하고 있습니다. 전 세계 의료비 증가, 특히 신경과 및 노인 의료 분야의 증가는 기존 치료법과 새로운 치료법 모두에 대한 광범위한 접근을 가능하게 하고 있습니다. 환자 옹호 및 간병인 지원 네트워크도 더 나은 치료 옵션에 대한 수요를 불러일으키고 공공정책에 영향을 미치는 역할을 하고 있습니다. 임상시험과 약물전달 기술의 통합으로 치료 결과의 모니터링과 치료의 개별화가 용이해지고 있습니다. 이러한 촉진요인은 치매가 초래하는 사회경제적 부담에 대한 인식의 증가와 함께 치매 치료제 시장이 지속적으로 성장하고, 혁신하며, 신경퇴행성 질환 관리의 복잡한 과제에 적응할 수 있도록 보장하고 있습니다.

부문

적응증(루이소체 치매, 파킨슨병성 치매, 알츠하이머병, 혈관성 치매, 기타 적응증), 약물 종류(MAO 억제제 클래스, 글루탐산 억제제 클래스, 콜린에스테라아제 억제제 클래스)

조사 대상 기업 사례

  • AbbVie Inc.
  • Acadia Pharmaceuticals
  • Amneal Pharmaceuticals
  • Biogen Inc.
  • Daiichi Sankyo Co., Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • GSK plc
  • Grifols, S.A.
  • H. Lundbeck A/S
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis International AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company
  • Teva Pharmaceutical Industries

AI 통합

우리는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범을 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.09.03

Global Dementia Drugs Market to Reach US$21.2 Billion by 2030

The global market for Dementia Drugs estimated at US$16.0 Billion in the year 2024, is expected to reach US$21.2 Billion by 2030, growing at a CAGR of 4.9% over the analysis period 2024-2030. Lewy Body Dementia, one of the segments analyzed in the report, is expected to record a 3.8% CAGR and reach US$7.7 Billion by the end of the analysis period. Growth in the Parkinson's Disease Dementia segment is estimated at 6.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.3 Billion While China is Forecast to Grow at 7.6% CAGR

The Dementia Drugs market in the U.S. is estimated at US$4.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.1 Billion by the year 2030 trailing a CAGR of 7.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.4% and 4.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.

Global Dementia Drugs Market - Key Trends & Drivers Summarized

Why Is the Demand for Dementia Drugs Becoming a Critical Global Health Priority?

Dementia, a progressive neurodegenerative disorder primarily affecting memory, cognition, and behavior, is increasingly being recognized as one of the most pressing global public health challenges. As populations age, particularly in developed and emerging economies, the incidence of dementia is rising rapidly, with Alzheimer’s disease accounting for the majority of cases. The social and economic burden of dementia is immense, affecting not only patients but also families, caregivers, and healthcare systems. This escalating prevalence is driving urgent demand for effective pharmacological treatments that can slow disease progression, manage symptoms, and improve quality of life. Currently, available dementia drugs are largely symptomatic, addressing neurotransmitter imbalances or behavioral complications rather than the underlying disease pathology. However, the growing urgency has spurred intensive research and development in disease-modifying therapies aimed at targeting amyloid plaques, tau tangles, and neuroinflammatory pathways. The need for better management options is heightened by the lack of curative treatments and the complex nature of the disease, which often coexists with other age-related conditions. Early diagnosis initiatives and growing awareness campaigns are prompting more individuals to seek treatment sooner, expanding the potential patient population for drug therapies. Healthcare providers and policymakers are increasingly prioritizing dementia management, which is resulting in more funding for clinical trials and more inclusive healthcare plans. This convergence of demographic, social, and medical factors is making the dementia drugs market a focal point of long-term strategic importance within the broader neurological therapeutics space.

How Are Scientific and Technological Advances Shaping the Future of Dementia Drug Development?

Advances in neuroscience, molecular biology, and biotechnology are reshaping the trajectory of dementia drug development, offering new hope for tackling the root causes of cognitive decline. In recent years, research has expanded beyond the traditional focus on cholinesterase inhibitors and NMDA receptor antagonists to explore novel targets including amyloid-beta aggregation, tau protein phosphorylation, synaptic plasticity, and neuroinflammation. Breakthroughs in genomics and proteomics are helping scientists identify biomarkers and genetic risk factors associated with different types of dementia, enabling more personalized and precise drug development. The introduction of advanced imaging techniques, such as PET scans and MRI-based volumetric analysis, allows for earlier diagnosis and more accurate tracking of disease progression, which is critical for assessing the effectiveness of new therapies. Clinical trial designs are also evolving, with adaptive trial models, real-world data integration, and digital cognitive assessment tools helping researchers gather more meaningful and timely insights. In parallel, pharmaceutical companies are leveraging artificial intelligence and machine learning to accelerate compound discovery, predict therapeutic outcomes, and optimize trial recruitment. Biologics and monoclonal antibodies targeting amyloid and tau proteins are progressing through regulatory pipelines, signaling a shift toward disease-modifying strategies. The accelerated approval of certain amyloid-targeting drugs in some markets, despite controversy, has renewed interest and investment in this area. Additionally, combination therapies that address multiple pathological processes simultaneously are gaining traction as a more comprehensive approach to treating dementia. These scientific and technological innovations are not only expanding the scope of therapeutic possibilities but also redefining the standards for efficacy and safety in the dementia drugs market.

What Trends Are Driving Market Expansion and Investment in Dementia Drug Therapies?

Multiple intersecting trends are fueling the expansion of the global dementia drugs market, reflecting shifts in demographics, healthcare priorities, and investment strategies. One of the most influential trends is the aging population, particularly in regions such as North America, Europe, Japan, and increasingly in parts of Asia and Latin America, where life expectancy is rising. With age being the single greatest risk factor for dementia, these demographic changes are translating into a larger patient base and a sustained market for therapeutic solutions. Simultaneously, public awareness campaigns and education efforts led by organizations such as the Alzheimer’s Association and the World Health Organization are breaking down stigma and encouraging earlier medical consultation, thereby increasing diagnosis rates. Healthcare systems are adapting by integrating cognitive screening into routine check-ups for older adults and expanding insurance coverage for dementia-related treatments. There is also a noticeable shift in investor sentiment, with venture capital firms and large pharmaceutical companies showing renewed interest in neurology and neurodegenerative disease research. Strategic partnerships between biotech startups and established drug manufacturers are becoming common, enabling faster innovation and broader clinical development. Additionally, regulators in several countries are showing greater flexibility in approving dementia treatments, especially those addressing unmet medical needs, which is accelerating market entry for promising candidates. Market diversification is another trend, with drug developers exploring therapies for various types of dementia, including vascular dementia, frontotemporal dementia, and Lewy body dementia, beyond Alzheimer’s disease. This broadening scope is ensuring that the market remains dynamic and responsive to a wider range of clinical presentations and patient needs.

What Are the Primary Drivers Propelling the Growth of the Dementia Drugs Market Worldwide?

The growth in the dementia drugs market is being driven by a convergence of medical, demographic, technological, and economic factors that collectively underscore the urgency and opportunity for therapeutic intervention. A primary driver is the exponential rise in dementia cases globally, spurred by aging populations and increased longevity, particularly in developed economies. This demographic shift is creating a continuously expanding pool of patients in need of long-term medical care, thus elevating the demand for effective pharmacological treatments. Another critical driver is the heightened focus on early diagnosis, which is being facilitated by improvements in diagnostic imaging, biomarker identification, and cognitive assessment tools. Earlier intervention increases the likelihood of therapeutic benefit and opens the door for preventive or disease-modifying strategies. Pharmaceutical and biotech companies are responding to this opportunity with aggressive investment in research and development, often backed by government grants and philanthropic funding. The evolution of regulatory frameworks, which now support fast-track approval pathways for drugs addressing significant unmet needs, is further encouraging innovation. Increasing global health expenditures, particularly in neurology and geriatric care, are enabling broader access to both existing and emerging therapies. Patient advocacy and caregiver support networks are also playing a role by driving demand for better treatment options and influencing public policy. Technological integration in clinical trials and drug delivery mechanisms is making it easier to monitor treatment outcomes and personalize care. These drivers, coupled with a growing recognition of the socioeconomic burden posed by dementia, are ensuring that the market for dementia drugs continues to grow, innovate, and adapt to the complex challenges of neurodegenerative disease management.

SCOPE OF STUDY:

The report analyzes the Dementia Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Indications (Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia, Other Indications); Drug Class (MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class, Cholinesterase Inhibitors Drug Class)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • AbbVie Inc.
  • Acadia Pharmaceuticals
  • Amneal Pharmaceuticals
  • Biogen Inc.
  • Daiichi Sankyo Co., Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • GSK plc
  • Grifols, S.A.
  • H. Lundbeck A/S
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis International AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company
  • Teva Pharmaceutical Industries

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Dementia Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Aging Global Population Throws the Spotlight on Long-Term Demand for Dementia Therapeutics
    • Surge in Early Diagnosis Rates Expands the Addressable Market for Dementia Drugs
    • Breakthroughs in Biomarker Research Strengthen the Business Case for Targeted Therapies
    • Regulatory Fast-Track Approvals Propel Growth of Novel Drug Candidates
    • Growing Caregiver Burden Drives Adoption of Symptom-Management Medications
    • Increased Awareness and Screening Programs Spur Uptake of Preventive Drug Therapies
    • Advances in Disease-Modifying Treatments Reshape the Therapeutic Landscape and Fuel Market Expansion
    • Rising Incidence of Alzheimer's and Related Dementias Creates Structural Growth Opportunities
    • Digital Therapeutics Integration Strengthens Value Proposition of Combined Drug Therapies
    • Evolving Reimbursement Policies Sustain Growth by Improving Drug Accessibility
    • Artificial Intelligence in Drug Discovery Drives Efficiency and Pipeline Innovation
    • Demand for Personalized Medicine Spurs Development of Genetically Tailored Dementia Drugs
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Dementia Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Dementia Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Dementia Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Dementia Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Lewy Body Dementia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Lewy Body Dementia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Lewy Body Dementia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Parkinson's Disease Dementia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Parkinson's Disease Dementia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Parkinson's Disease Dementia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Alzheimer's Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Alzheimer's Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Alzheimer's Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Vascular Dementia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Vascular Dementia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Vascular Dementia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for MAO Inhibitors Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for MAO Inhibitors Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for MAO Inhibitors Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Glutamate Inhibitors Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Glutamate Inhibitors Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Glutamate Inhibitors Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Cholinesterase Inhibitors Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Cholinesterase Inhibitors Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Cholinesterase Inhibitors Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Dementia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • JAPAN
    • Dementia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • CHINA
    • Dementia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: China 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • EUROPE
    • Dementia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Dementia Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Dementia Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Dementia Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • FRANCE
    • Dementia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: France 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • GERMANY
    • Dementia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Dementia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Dementia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Dementia Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Dementia Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Dementia Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Dementia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • INDIA
    • Dementia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: India 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Dementia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Dementia Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Dementia Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Dementia Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Dementia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Dementia Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Dementia Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Dementia Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • AFRICA
    • Dementia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제